2245085-40-7

Basic information

• Product Name: tert-butyl (S)-1-((S)-tert-butylsulfinylamino)-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-carboxylate
• CAS NO: 2245085-40-7
• Molecular Weight: 406.59
• Mol File: 2245085-40-7.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl (S)-1-((S)-tert-butylsulfinylamino)-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (S)-1-((S)-tert-butylsulfinylamino)-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-carboxylate(2245085-40-7)
• EPA Substance Registry System: tert-butyl (S)-1-((S)-tert-butylsulfinylamino)-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-carboxylate(2245085-40-7)

Safety Data

• Hazardous Substances Data: 2245085-40-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl (S)-1-((S)-tert-butylsulfinylamino)-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-carboxylate is used as a potential pharmaceutical compound for its possible biological activity. The presence of the tert-butylsulfinylamino and spiro[indene-2,4'-piperidine] moieties indicates that tert-butyl (S)-1-((S)-tert-butylsulfinylamino)-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-carboxylate may have applications in drug development, particularly if it exhibits desirable pharmacological properties upon further investigation.
Used in Chemical Research:
In the field of chemical research, tert-butyl (S)-1-((S)-tert-butylsulfinylamino)-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-carboxylate serves as a subject of study for understanding the synthesis and properties of complex chiral molecules. Its unique structure and potential stereoisomers provide opportunities for researchers to explore the effects of chirality on chemical reactivity and potential applications in various fields.

Upstream product

• 136080-25-6 spiro[indene-2,4’-piperidin]-1(3H)-one 
• 1228079-29-5 tert-butyl 1-oxo-1,3-dihydrospiro[indene-2,4’-piperidine]-1’-carboxylate 
• 196929-78-9 (R)-2-methylpropane-2-sulfinamide 
• 83-33-0 inden-1-one 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 100-39-0 benzyl bromide 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 167263-10-7 4-benzyl-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 

Downstream Products

• 2245085-41-8 (R)-N-((S)-1,3-dihydrospiro[indene-2,4’-piperidin]-1-yl)-2-methylpropane-2-sulfinamide 
• 2306254-23-7 (S)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine hydrochloride 
• 2245085-41-8 (S)-N-((S)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfinamide 
• 2306254-23-7 (S)-1,3-dihydrospiro[indene-2,4′-piperidine]-1-amine dihydrochloride 

Relevant articles and documents

SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF

Provided herein are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF

The present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative, a preparation method therefor, and the medical uses thereof. Particularly, the present invention relates to a pyrimidine and a five-membered nitrogen hetero

SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF

Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

Compound serving as SHP2 inhibitor and application thereof

The invention belongs to the field of medical chemistry, relates to a compound serving as an SHP2 inhibitor and an application of the compound, and particularly provides a compound shown in a formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug of the compound, processes for the preparation, pharmaceutical compositions containing these compounds and the use of these compounds or compositions for the treatment of SHP2 mediated diseases.

REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a regulator of nitrogen-containing heteroaromatic derivatives, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protein tyrosine phosphatase-2C (SHP2) inhibitor in the treatment of diseases or conditions such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colorectal cancer, wherein the definition of each substituent in the general formula (I) is the same as that in the description.

Salt of nitrogen-containing heteroaromatic derivative and crystal form thereof

The invention relates to a salt of a nitrogen-containing heteroaromatic derivative and a crystal form thereof. The invention specifically relates to a salt with a general formula (I) and a crystal form thereof. A preparation method and a pharmaceutical composition containing the salt of the derivative and a crystal form thereof, as a protein tyrosine phosphatase - 2C (SHP2) inhibitor, and application thereof to treatment of diseases or diseases such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colon cancer.

Pyrazinothiazole compound and application thereof, and pharmaceutical composition containing pyrazinothiazole compound

The invention discloses a pyrazinothiazole compound, an application of the pyrazinothiazole compound, and a pharmaceutical composition containing the pyrazinothiazole compound, and provides a pyrazinothiazole compound represented by a formula A or a pharmaceutically acceptable salt of the pyrazinothiazole compound. The pyrazinothiazole compound provided by the invention has relatively good SHP2 inhibitory activity.

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.

IMIDAZOPYRIMIDINE DERIVATIVES

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.

PROTEIN TYROSINE PHOSPHATASE INHIBITORS

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.